| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Monopar Therapeutics Inc (NASDAQ: MNPR)
MNPR Technical Analysis
5
| As on 9th Jun 2023 MNPR STOCK Price closed @ 0.94 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.43 & Strong Sell for SHORT-TERM with Stoploss of 3.12 we also expect STOCK to react on Following IMPORTANT LEVELS. |
MNPRSTOCK Price
| Open | 0.90 | Change | Price | % |
| High | 0.98 | 1 Day | 0.02 | 2.17 |
| Low | 0.90 | 1 Week | -0.04 | -4.08 |
| Close | 0.94 | 1 Month | -0.22 | -18.97 |
| Volume | 151500 | 1 Year | -3.00 | -76.14 |
| 52 Week High 4.43 | 52 Week Low 0.85 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| MNPR Daily Charts |
MNPR Intraday Charts |
Whats New @ Bazaartrend |
MNPR Free Analysis |
|
|
MNPR Important Levels Intraday
| RESISTANCE | 1.09 |
| RESISTANCE | 1.04 |
| RESISTANCE | 1.01 |
| RESISTANCE | 0.98 |
| SUPPORT | 0.90 |
| SUPPORT | 0.87 |
| SUPPORT | 0.84 |
| SUPPORT | 0.79 |
MNPR Forecast May 2024
| 4th UP Forecast | 3.54 |
| 3rd UP Forecast | 2.71 |
| 2nd UP Forecast | 2.19 |
| 1st UP Forecast | 1.68 |
| 1st DOWN Forecast | 0.2 |
| 2nd DOWN Forecast | -0.31 |
| 3rd DOWN Forecast | -0.83 |
| 4th DOWN Forecast | -1.66 |
MNPR Weekly Forecast
| 4th UP Forecast | 1.88 |
| 3rd UP Forecast | 1.58 |
| 2nd UP Forecast | 1.39 |
| 1st UP Forecast | 1.21 |
| 1st DOWN Forecast | 0.67 |
| 2nd DOWN Forecast | 0.49 |
| 3rd DOWN Forecast | 0.30 |
| 4th DOWN Forecast | 0.00 |
MNPR Forecast2024
| 4th UP Forecast | 8.78 |
| 3rd UP Forecast | 6.27 |
| 2nd UP Forecast | 4.71 |
| 1st UP Forecast | 3.16 |
| 1st DOWN Forecast | -1.28 |
| 2nd DOWN Forecast | -2.83 |
| 3rd DOWN Forecast | -4.39 |
| 4th DOWN Forecast | -6.9 |
Monopar Therapeutics Inc ( NASDAQ USA Symbol : MNPR )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
MNPR Business Profile
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. It also has a collaboration agreement with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois. Address: 1000 Skokie Boulevard, Wilmette, IL, United States, 60091
� 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service